The agreement grants MeiraGTx exclusive rights to ZipBio’s first-in-class therapies targeting the complement pathway for Geographic Atrophy, a progressive eye disease with significant unmet medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results